Making HIV imaging more accessible through automated production of imaging agents.
Official title: Improving availability of ImmunoPET via automation of radio-synthesis and quality control of antibody-based HIV imaging PET tracers on a single platform.
Funded at Trace-Ability, INC. · NIH-11010813 · Data updated 2026-11-12
This study is working on making a new imaging technique for HIV easier and more affordable for hospitals to use, so that more patients can get better diagnoses and treatment options.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Trace-Ability, INC. NIH-funded |
| Lab location | 1 site (Van Nuys, United States) |
| Project start | January 15, 2024 |
| Project end | December 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $1,000,000 |
| NIH project number | 5R44AI162202-03 |
| Project ID | NIH-11010813 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with HIV who may benefit from advanced imaging techniques for better disease management.
✕Less likely to help
Patients who do not have HIV or related conditions may not receive any benefit from this research.
What this research studies
This research focuses on improving the availability of ImmunoPET imaging for HIV by automating the production of radiolabeled antibodies. The project aims to develop a compact and affordable system called Tracer-ONE that simplifies the entire process of creating these imaging agents, making it possible for more medical facilities to produce them. By streamlining the production and quality control processes, the goal is to enable wider access to this innovative imaging technique, which can provide critical insights into biological processes related to HIV. Patients will benefit from enhanced diagnostic capabilities that can lead to better treatment options.
Why it matters
Potential benefit: If successful, this research could significantly increase access to advanced imaging techniques for HIV, leading to improved patient outcomes.
How similar studies have gone: Other research has shown success in automating the production of medical imaging agents, indicating that this approach has potential for similar advancements.
Where this research is happening
-
Trace-Ability, INC.
Van Nuys, United States Active
Researchers
- Principal investigator: Elizarov, Arkadij — Trace-Ability, INC.
- Study coordinator: Elizarov, Arkadij
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.